Use of glucosamine and chondroitin in relation to mortality
- 505 Downloads
Glucosamine and chondroitin are products commonly used by older adults in the US and Europe. There is limited evidence that they have anti-inflammatory properties, which could provide risk reduction of several diseases. However, data on their long-term health effects is lacking. To evaluate whether use of glucosamine and chondroitin are associated with cause-specific and total mortality. Participants (n = 77,510) were members of a cohort study of Washington State (US) residents aged 50–76 years who entered the cohort in 2000–2002 by completing a baseline questionnaire that included questions on glucosamine and chondroitin use. Participants were followed for mortality through 2008 (n = 5,362 deaths). Hazard ratios (HR) for death adjusted for multiple covariates were estimated using Cox models. Current (baseline) glucosamine and chondroitin use were associated with a decreased risk of total mortality compared to never use. The adjusted HR associated with current use of glucosamine (with or without chondroitin) was 0.82 (95 % CI 0.75–0.90) and 0.86 (95 % CI 0.78–0.96) for chondroitin (included in two-thirds of glucosamine supplements). Current use of glucosamine was associated with a significant decreased risk of death from cancer (HR 0.87 95 % CI 0.76–0.98) and with a large risk reduction for death from respiratory diseases (HR 0.59 95 % CI 0.41–0.83). Use of glucosamine with or without chondroitin was associated with reduced total mortality and with reductions of several broad causes of death. Although bias cannot be ruled out, these results suggest that glucosamine may provide some mortality benefit.
KeywordsGlucosamine Chondroitin Supplements Mortality Cohort Cancer
This work was supported by grants R01-CA142545, R25-CA94880, and K05-CA154337 from the National Cancer Institute (US).
- 3.Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55.PubMedCrossRefGoogle Scholar
- 10.Kantor ED LJ, Vaughan TL, Peters U, Rehm CD, White E. Association of specialty supplement use with C-reactive protein. Am J Epidemiol 2012. (in press.).Google Scholar
- 13.Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(21 Suppl 1):II2–10.Google Scholar
- 22.U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans. Washington, DC: US GPO; 2005.Google Scholar
- 23.Organization WH. International statistical classification of diseases and related health problems, 10th revision. Version for 2007. Geneva: World Health Organization.Google Scholar
- 35.Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24(5B):3177–84.Google Scholar
- 40.Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood). 2005;230(4):255–62.Google Scholar
- 44.Nakamura H, Nishioka K. Effects of glucosamine/chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. Jpn J Rheum Joint Surg. 2002;21(2):175–84.Google Scholar